Acrivon Therapeutics, Inc. Common Stock
ACRV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $0 | $0 |
| Gross Profit | -$1 | -$1 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $64 | $45 | $24 | $14 |
| G&A Expenses | $25 | $21 | $9 | $2 |
| SG&A Expenses | $25 | $21 | $9 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | $0 | $0 | $0 |
| Operating Expenses | $88 | $67 | $33 | $16 |
| Operating Income | -$89 | -$67 | -$33 | -$16 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $9 | $7 | $1 | -$0 |
| Pre-Tax Income | -$81 | -$60 | -$31 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$81 | -$60 | -$31 | -$16 |
| % Margin | – | – | – | – |
| EPS | -2.1 | -2.74 | -1.42 | -1.26 |
| % Growth | 23.4% | -93% | -12.7% | – |
| EPS Diluted | -2.1 | -2.74 | -1.42 | -1.26 |
| Weighted Avg Shares Out | 38 | 22 | 22 | 13 |
| Weighted Avg Shares Out Dil | 38 | 22 | 22 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$80 | -$60 | -$32 | -$16 |
| % Margin | – | – | – | – |